BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15888569)

  • 1. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
    Nagao S; Kusaka M; Nishii K; Marunouchi T; Kurahashi H; Takahashi H; Grantham J
    J Am Soc Nephrol; 2005 Jul; 16(7):2052-62. PubMed ID: 15888569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
    Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
    Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
    Yamaguchi T; Nagao S; Wallace DP; Belibi FA; Cowley BD; Pelling JC; Grantham JJ
    Kidney Int; 2003 Jun; 63(6):1983-94. PubMed ID: 12753285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
    Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
    Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
    Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
    Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.
    Cowley BD; Rupp JC; Muessel MJ; Gattone VH
    Am J Kidney Dis; 1997 Feb; 29(2):265-72. PubMed ID: 9016899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease.
    Su Z; Wang X; Gao X; Liu Y; Pan C; Hu H; Beyer RP; Shi M; Zhou J; Zhang J; Serra AL; Wüthrich RP; Mei C
    J Intern Med; 2014 Nov; 276(5):470-85. PubMed ID: 24494798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classifying chemical mode of action using gene networks and machine learning: a case study with the herbicide linuron.
    Ornostay A; Cowie AM; Hindle M; Baker CJ; Martyniuk CJ
    Comp Biochem Physiol Part D Genomics Proteomics; 2013 Dec; 8(4):263-74. PubMed ID: 24013142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
    Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
    Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
    Pey R; Bach J; Schieren G; Gretz N; Hafner M
    In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased uterine androgen receptor protein abundance results in implantation and mitochondrial defects in pregnant rats with hyperandrogenism and insulin resistance.
    Zhang Y; Hu M; Yang F; Zhang Y; Ma S; Zhang D; Wang X; Sferruzzi-Perri AN; Wu X; Brännström M; Shao LR; Billig H
    J Mol Med (Berl); 2021 Oct; 99(10):1427-1446. PubMed ID: 34180022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway.
    Yamaguchi T; Pelling JC; Ramaswamy NT; Eppler JW; Wallace DP; Nagao S; Rome LA; Sullivan LP; Grantham JJ
    Kidney Int; 2000 Apr; 57(4):1460-71. PubMed ID: 10760082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
    Wahl PR; Le Hir M; Vogetseder A; Arcaro A; Starke A; Waeckerle-Men Y; Serra AL; Wuthrich RP
    Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.